Next Article in Journal
Driving Forces Behind the Past and Future Emergence of Personalized Medicine
Next Article in Special Issue
Understanding the Economic Value of Molecular Diagnostic Tests: Case Studies and Lessons Learned
Previous Article in Journal
Teenagers as a Moving Target: How Can Teenagers Be Encouraged to Accept Treatment?
Previous Article in Special Issue
Aligning the Economic Value of Companion Diagnostics and Stratified Medicines
Open AccessReview

Structured Decision-Making: Using Personalized Medicine to Improve the Value of Cancer Care

1
Center for Learning Health Care, Duke Clinical Research Institute, PO Box 17969, Durham, NC 27715, USA
2
Division of Medical Oncology, Department of Medicine, Duke University Medical Center Box 3436, Durham, NC 27710, USA
*
Author to whom correspondence should be addressed.
J. Pers. Med. 2013, 3(1), 1-13; https://doi.org/10.3390/jpm3010001
Received: 22 November 2012 / Revised: 19 December 2012 / Accepted: 19 December 2012 / Published: 27 December 2012
Cancer care is often inconsistently delivered with inadequate incorporation of patient values and objective evidence into decision-making. Utilization of time limited trials of care with predefined decision points that are based on iteratively updated best evidence, tools that inform providers about a patient’s experience and values, and known information about a patient’s disease will allow superior matched care to be delivered. Personalized medicine does not merely refer to the incorporation of genetic information into clinical care, it involves utilization of the wide array of data points relevant to care, many of which are readily available at the bedside today. By pushing uptake of personalized matching available today, clinicians can better address the triple aim of improved health, lowers costs, and enhanced patient experience, and we can prepare the health care landscape for the iterative inclusion of progressively more sophisticated information as newer tests and information become available to support the personalized medicine paradigm. View Full-Text
Keywords: personalized medicine; oncology; comparative effectiveness research; cancer; structured decision-making; time limited trials personalized medicine; oncology; comparative effectiveness research; cancer; structured decision-making; time limited trials
Show Figures

Figure 1

MDPI and ACS Style

Hirsch, B.R.; Abernethy, A.P. Structured Decision-Making: Using Personalized Medicine to Improve the Value of Cancer Care. J. Pers. Med. 2013, 3, 1-13.

Show more citation formats Show less citations formats

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop